AUG 01, 2016 12:21 PM PDT

$1.57 Million Grant to Combat Hospital-Acquired Infections

WRITTEN BY: Xuan Pham
Much like the bacteria that build plaque in your teeth, bacteria can colonize medical implants as slimy films that cause infections. Furthermore, these infections are often difficult to treat because the bacteria, especially those from hospitals, have become resistant to antibiotics. To reduce these types of infections, the National Institute of Health (NIH) recently awarded Clemson University scientists a $1.57 million grant aimed at a new detection technology.

Biofilm on a catheter | Image: wikimedia

Clemson’s team hope to tackle hospital-acquired infections through a dye-based sensor that’s sensitive to the acid levels on the surface of medical implants.

"What we're attempting to do is quite challenging," said Jeffrey Anker, Associate Professor of Chemistry at Clemson, and leader of the new project efforts. "We're trying to put a sensor on a plate that will be able to reside in a human body for a reasonable period of time in order to monitor changes in local acidity that will detect infection. Bacteria produce a lot of acids. A human's immune system also produces acids. So if low pH is detected on the surface of an implant, it will be reasonable to assume that the implant is infected. But our research will also delve more into these aspects to determine their validity."

In its planktonic form, the bacteria grow as single, independent cells, causing acute infections that can be treated with antibiotics. In its biofilm form, the bacteria exist as aggregated colonies that secrete a slimy film, which serves to protect them against the environment. More than 80% of infections are attributed to biofilms. In addition to growing on medical devices like dialysis catheters and contact lenses, biofilms can also dwell inside patients -- in the respiratory, gastrointestinal and urinary tracts, oral cavities, eyes, ears, wounds, heart and cervix. Because the slime protects them against antibiotics, some infections by biofilms are resistant to drugs and develop into a chronic state.

"Bacterial colonization of medical implants is a major cause of device failure and often requires device removal coupled with long-term antibiotic treatment," said Anker. "However, detection is challenging at early stages when the bacteria are localized to inaccessible regions of the implant. Our research will focus on developing sensors that will coat the implant. Then we'll use X-ray beams to scan the sensors, enabling us to detect and monitor the infection."
 

Most current technologies only detect bacterial infection when things get really bad for the patients. But when the infection is severe, antibiotics may not be enough for the drug-resistant biofilms. Even if the bacteria aren’t resistant, the slime surface enables some colonies to escape treatment and then sprouting new infections. “At this point, the implant typically needs to be tediously cleansed during a surgical procedure called debridement. If the biofilm isn't fully mature, this is sometimes effective. But if the biofilm has been long established, then debridement usually isn't good enough. The implant will then need to be removed and the remaining infection treated with antibiotics before a new implant is inserted,” explained Anker.

With the new research, the Clemson team hope to finally give doctors a leg-up on bacterial infections. Instead of playing catch-up with the bacteria, early detection could prompt faster and more effective treatments. And that’s important for everyone, as infections add a significant amount of burden on a health care system that’s already very stressed.
 

Additional source: Clemson University press release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 29, 2020
Drug Discovery & Development
Cycling Molecules into Drug Candidates
SEP 29, 2020
Cycling Molecules into Drug Candidates
Statistics show that just 1 in 5,000 drug candidates ever makes it from the lab to the pharmacy. In a process that can t ...
NOV 05, 2020
Clinical & Molecular DX
Digging DEEP into Metabolomic Space
NOV 05, 2020
Digging DEEP into Metabolomic Space
Metabolomics is an umbrella term encompassing lipidomics and the study of smaller polar metabolites.  As such, more ...
NOV 09, 2020
Cancer
A Prognostic Expression Profile for Osteosarcoma
NOV 09, 2020
A Prognostic Expression Profile for Osteosarcoma
Tireless research goes into every cancer diagnostic tools and new therapy. Many types of cancer have made giant steps fo ...
NOV 24, 2020
Cancer
Using Restfulness as a Metric for Measuring Sleep Quality and Cardiovascular Risk
NOV 24, 2020
Using Restfulness as a Metric for Measuring Sleep Quality and Cardiovascular Risk
Did you know sleeping is great? Apparently, getting a full eight hours every night can make you look fabulous and solve ...
DEC 14, 2020
Clinical & Molecular DX
STR Genotyping for Human Sample Identification
DEC 14, 2020
STR Genotyping for Human Sample Identification
Human sample identification is an essential element of many research projects employing human cells, tissues, or mixture ...
JAN 14, 2021
Clinical & Molecular DX
Tip of the Iceberg: Inaccuracies in Prostate Cancer Diagnostics
JAN 14, 2021
Tip of the Iceberg: Inaccuracies in Prostate Cancer Diagnostics
  Only 10 percent of icebergs are visible on the surface of the water; the remaining 90 percent remains submerged. ...
Loading Comments...